Clinicopathological and Prognostic Significance of CBX3 Expression in Human Cancer: a Systematic Review and Meta-analysis

Table 2

OR for the relationship between positive CBX3 expression and clinicopathological features.

Categories	Studies no.	Case no.	Pooled OR (95% CI)	Model	Heterogeneity
						value
Age (≥65 vs. <65years)	3	200	1.51 (0.84, 2.69)	Fixed	0%	0.81
Age (≥60 vs. <60years)	2	224	0.65 (0.37, 1.14)	Fixed	0%	0.76
Age (≥50 vs. <50years)	2	427	1.13 (0.75, 1.68)	Fixed	0%	0.62
Gender (male vs. female)	7	851	0.86 (0.61, 1.22)	Fixed	29%	0.21
Tumor size (>5 vs. ≤5 cm)	4	593	1.60 (1.12, 2.28)	Fixed	2%	0.38
Tumor size (>3 vs. ≤3 cm)	2	170	0.69 (0.36, 1.34)	Fixed	0%	0.94
Lymph node metastasis (N+ vs. N0)	7	567	2.96 (1.42, 6.20)	Random	66%	0.007
Distant metastasis (M+ vs. M0)	3	211	1.24 (0.35, 4.37)	Fixed	0%	0.86
Degree of differentiation (well+moderate vs. poor)	5	645	0.97 (0.64, 1.49)	Fixed	0%	0.76

Abbreviations: OR: odds ratio.